PriceTargets.com logo

Viracta Therapeutics - VIRX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $4.05
  • Forecasted Upside: 19,185.71%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$0.02 As of 04/1/2025 04:30 PM ET
▼ -0.0025 (-10.64%)

This chart shows the closing price for VIRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
FebMar$0.02Closing price on 04/01/25:
Get New Viracta Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VIRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VIRX

Analyst Price Target is $4.05
▲ +19,185.71% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Viracta Therapeutics in the last 3 months. The average price target is $4.05, with a high forecast of $11.00 and a low forecast of $0.25. The average price target represents a 19,185.71% upside from the last price of $0.02.

This chart shows the closing price for VIRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
3/246/249/2412/244/254/26$070$2.76$5.50$8.25$11Closing price on 04/01/25: $0.02High$11.00Average$4.05Low$0.25




Current Consensus is Moderate Buy

The current consensus among 5 investment analysts is to moderate buy stock in Viracta Therapeutics. This rating has held steady since August 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/10/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/8/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/7/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/6/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/4/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
1/2/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/3/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
4/2/2025

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/27/2024Rodman & RenshawReiterated RatingBuy ➝ Neutral$3.50 ➝ $0.25
11/14/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$4.00 ➝ $2.00
8/16/2024Leerink PartnersDowngradeOutperform ➝ Market Perform$5.00 ➝ $3.00
8/15/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$6.00 ➝ $4.00
5/23/2024OppenheimerLower TargetOutperform ➝ Outperform$13.00 ➝ $11.00
4/17/2024OppenheimerReiterated RatingOutperform ➝ Outperform$13.00
4/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$4.00
1/5/2024HC WainwrightLower TargetBuy ➝ Buy$10.00 ➝ $4.00
11/10/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$7.00 ➝ $6.00
10/5/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$7.00
8/15/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$7.00
8/15/2023SVB SecuritiesLower TargetOutperform ➝ Outperform$10.00 ➝ $5.00
8/15/2023HC WainwrightReiterated RatingBuy ➝ Buy$10.00
7/5/2023HC WainwrightLower Target$33.00 ➝ $10.00
5/10/2023HC WainwrightLower Target$35.00 ➝ $33.00
3/27/2023OppenheimerBoost TargetOutperform$14.00 ➝ $16.00
3/14/2023HC WainwrightReiterated RatingBuy$35.00
3/14/2023Royal Bank of CanadaReiterated RatingOutperform$8.00
11/11/2022Royal Bank of CanadaLower TargetOutperform$10.00 ➝ $8.00
5/12/2022HC WainwrightReiterated RatingBuy
2/1/2022Royal Bank of CanadaInitiated CoverageOutperform$10.00
11/14/2021Leerink PartnersReiterated RatingBuy$18.00
10/7/2021HC WainwrightReiterated RatingBuy$35.00
8/15/2021Leerink PartnersReiterated RatingBuy$18.00
7/26/2021HC WainwrightReiterated RatingBuy$35.00
5/3/2021Leerink PartnersInitiated CoverageOutperform$18.00
5/3/2021HC WainwrightInitiated CoverageBuy$35.00
4/26/2021Leerink PartnersInitiated CoverageOutperform
3/25/2021Evercore ISIInitiated CoverageOutperform$45.00
2/26/2021OppenheimerBoost TargetOutperform$12.00 ➝ $36.00
(Data available from 4/2/2020 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/4/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/4/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/3/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/3/2024
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/2/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
2/1/2025
  • 0 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/3/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/2/2025

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Viracta Therapeutics logo
Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.
Read More

Today's Range

Now: $0.02
Low: $0.02
High: $0.03

50 Day Range

MA: $0.05
Low: $0.01
High: $0.17

52 Week Range

Now: $0.02
Low: $0.01
High: $1.31

Volume

177,100 shs

Average Volume

1,070,323 shs

Market Capitalization

$834.62 thousand

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.44

Frequently Asked Questions

What sell-side analysts currently cover shares of Viracta Therapeutics?

The following sell-side analysts have issued research reports on Viracta Therapeutics in the last year: HC Wainwright, Leerink Partners, Oppenheimer Holdings Inc., Rodman & Renshaw, and Royal Bank of Canada.
View the latest analyst ratings for VIRX.

What is the current price target for Viracta Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Viracta Therapeutics in the last year. Their average twelve-month price target is $4.05, suggesting a possible upside of 19,185.7%. Oppenheimer Holdings Inc. has the highest price target set, predicting VIRX will reach $11.00 in the next twelve months. Rodman & Renshaw has the lowest price target set, forecasting a price of $0.25 for Viracta Therapeutics in the next year.
View the latest price targets for VIRX.

What is the current consensus analyst rating for Viracta Therapeutics?

Viracta Therapeutics currently has 2 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for VIRX.

What other companies compete with Viracta Therapeutics?

Other companies that are similar to Viracta Therapeutics include Virax Biolabs Group, Ensysce Biosciences, Purple Biotech, Sonoma Pharmaceuticals and Pasithea Therapeutics. Learn More about companies similar to Viracta Therapeutics.

How do I contact Viracta Therapeutics' investor relations team?

Viracta Therapeutics' physical mailing address is 2533 S. COAST HWY. 101 SUITE 210, CARDIFF CA, 92007. The company's listed phone number is (858) 400-8470 and its investor relations email address is bjerkholt@sunesis.com. The official website for Viracta Therapeutics is www.viracta.com. Learn More about contacing Viracta Therapeutics investor relations.